Evidence map›Paper›PMID 42074516›Full record

ArticleGenes2026

Association of the

Sara Mimi Atmani, Faiza Bouldjennet, Yasmine Khalili, Nabyla Feghoul, Amel Dammene Debbih

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sara Mimi AtmaniLaboratory of Cellular and Molecular Biology, Faculty of Biological Sciences, University of Sciences and Technology Houari Boumediene, PB 32, El Alia, Bab Ezzouar, Algiers 16111, Algeria.ORCID 0000-0001-6786-5744
Faiza BouldjennetLaboratory of Cellular and Molecular Biology, Faculty of Biological Sciences, University of Sciences and Technology Houari Boumediene, PB 32, El Alia, Bab Ezzouar, Algiers 16111, Algeria.
Yasmine KhaliliDepartment of Obstetrics and Gynaecology, Ibn-Ziri Hospital, EPH Bologhine, Algiers 16000, Algeria.
Nabyla FeghoulDepartment of Obstetrics and Gynaecology, El-Tayeb Bougasmi Hospital, EPH Zeralda, Algiers 16000, Algeria.
Amel Dammene DebbihDepartment of Obstetrics and Gynaecology, Ibn-Ziri Hospital, EPH Bologhine, Algiers 16000, Algeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesPreeclampsia (PE) is the primary cause of maternal and perinatal morbidity and mortality on a global scale. It is driven by a multifactorial aetiology, in which genetic factors involved in blood pressure regulation, including the endothelial nitric oxide synthase (

methodsA total of 305 Algerian women, comprising 124 patients with PE and 181 healthy controls, were genotyped for two polymorphisms: intron 4 variable number tandem repeat (VNTR) (4a/4b) and the -786 T>C promoter variant. Genotyping was performed using standard polymerase chain reaction (PCR) for VNTR and polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) for the -786 T>C variant.

resultsOur results revealed no significant difference in the allelic or genotypic frequencies of the -786 T>C polymorphism between the cases and controls (

conclusionsThese findings support the potential role of the

Indexed as

Genetic Predisposition to DiseaseMinisatellite RepeatsNitric Oxide Synthase Type IIIPre-EclampsiaAdultAlgeriaCase-Control StudiesFemaleGene FrequencyGenotypeHumansIntronsPolymorphism, Restriction Fragment LengthPolymorphism, Single NucleotidePregnancySeverity of Illness IndexNitric Oxide Synthase Type IIINOS3 protein, human−786 T>C varianteNOSintron 4 VNTRPCR-RFLPpreeclampsia

Identifiers

PMID42074516
PMCPMC13116626

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.